has been allowed to be retained by the producer in each drug;

(g) whether there is any proposal to reconsider the decision; and

(h) if so, by when?

THE MINISTER OF PETROLEUM AND CHEMICALS AND PARLIAMENTARY AFFAIRS (SHRI SATYA PRAKASH MALAVIYA): (a) and (b) Kelkar Committee recommended that in order to provide incentive to reduce costs through research & development expenditure, Government should allow 50 per cent of the reduction to be retained by the producers.

(c) and (d) The recommendation of the Kelkar Committee to this effect was accepted in principle subject to exact identification of Research and Development efforts.

(e) and (f) Some recommendations of the BICP incorporating this decision of the Kelkar Committee have been received. Government have, however, not decided any of the recommendation so far.

(g) and (h) There is no proposal at present to reconsider the decision of the Government on this issue.

Discounts on Products of IDPL and HAL

201. SHRI BEKAL UTSAHI:
SHRI RAJNI RANJAN SAHU:

Will the Minister of PETROLEUM AND CHEMICALS be pleased to state:

(a) what are the names of the products and percentage of discounts being offered by IDPL and HAL over and above the Trade Commission;

(b) whether it is a fact that this is reducing the realisation of the companies and resulting in losses;

(c) if so, what are the reasons for providing such discounts;

(d) whether it is also a fact that consumer prices are very high and the middlemen are taking away the benefit of such discounts; and

(e) what steps have been taken to rectify the situation?

THE DEPUTY MINISTER IN THE MINISTRY OF PETROLEUM AND CHEMICALS AND THE DEPUTY MINISTER IN THE MINISTRY OF COMMUNICATIONS (SHRI JAI PARKASH): (a) As regards Indian Drugs and Pharmaceuticals, details furnished by it are given in the statement. Hindustan Antibiotics Ltd. has reported that it does not give any discounts on products over and above the trade margin and that for special compaigns, bonus quantities are given for bulk stocking for limited period to off set the inventory carrying costs.

(b) Hindustan Antibiotics Limited has reported that it has not incurred any losses. According to Indian Drugs and Pharmaceuticals Ltd. there are losses.

(c) Indian Drugs and Pharmaceuticals has stated that discounts are offered to match competitive prices in the market and that special discounts and incentives are offered to get rid of stocks faster particularly when their shelf-life is limited. This practice is followed not only by the IDPL but by the entire drug industry.

(d) No, Sir.

(e) Does not arise.

Statement

Discounts on Products of Indian Drugs and Pharmaceuticals Ltd.

S. No.	Name of Product	%age of discount
1	Benzyl Penicillin 5 lac.	20
2	Benzyl Penicillin 10 lac.	15
	Fortified Procain Penicillin 4 lac.	
	Streptomycin 1 gm. and 0·75 gm. & Streptopenicillin 1/2 gm.	
3	Fortified Procain Pen. 20 lac.	10
4	Fortified Procain Pen. 40 lac.	5
5	Penicillin Streptomycin 2·5 gm.	5
6	Broacil Inj. 500 mg./Sod. Amp. Inj. 500 mg and Sod. Amp. Inj. 250 mg.	20
7	Famcin 150 mg. 25×4, Femcin 300 mg. 10×4	20
8	Famcin 450 mg. 10×3 & 600 mg. 10×3 & Famcin—H	10
9	Tetracycline Caps. 250 mg. 10×10	13.3
10	(a) Broacil Caps 250 mg. 25×4	15
	(b) Broacil Caps. 500 mg. 10×4	5
11	Broacil Dry Syp.	10
12	Idimox caps. 250mg. 10×6	15
13	Idimox Caps. 500 mg. 10×6	5
14	Idimox Dry Syp.	10
15	Cephal Caps. 250 mg. 10×4	15
16	Cephal Caps. 500 mg. 10×4	5
17	Cephal Dry Syp.	10
18	Boric Acid (all packings)	10
19	Zinc Oxide (all packings)	10
20	Glycerine (all packings)	20
21	INH 300 mg. 1000s	5
22	Paracetomol Tubs. 10×10	5
23	Idiquine Tabs. 12×10	5
24	Idiflox 400 mg. 10×4 & 800 mg. 10×2	20
25	Idilin 250 mg. 10×10	13.3
26	Idilin 500 mg. 25×4	5
27	Oxytetracycline Inj. 20 ml.	5
28	Calmod Tabs. 10×10	30

S. No.	Name of Product	%age of Discount
29	Idisules Caps. 100s (other than gift pack).	10
30	Analgin Tabs. 10×10	20
31	Idibend Tabs. 10×6	15
32	IBF SR. 10×10	20
33	Sulphaguanidine 10×10	10
34	Chloramphenicol Caps. 1000s	10
35	Benzathin Pen. 6 lac. 12 lac & 24 lac.	10
36	Idivit Tabs. 10×10	10
37	Idivit Inj. 3 ml. ×50	10
	Special Discount for Stockists/Doctors	
1	Paracetamol Tabs. 1000s 24 tins of col. 1 price	15
2	Tetracycline Caps. 250mg. 1000s	24.3
3	Ampicillin Caps. 250mg. 500s	11·7
4	Ampicillin Caps. 250 mg. 100s	29
5	Sulphadimidine Tabs. 1000s	8.9
6	Analgin Tabs. 1000s	6·3

Production of drugs

202. SHRI BEKAL UTSAHI:
SHRI RAJNI RANJAN SAHU:

Will the Minister of PETROLEUM AND CHEMICALS be pleased to state:

(a) what was the production of monitored drugs during the last three years, year-wise;

(b) what are the names of drugs where production has declined and what are the reasons for this decline in production;

(c) what remedial steps have been taken in this regard;

(d) what are the names of drugs which are being produced from intermediate stage and since when each is being produced; and

(e) what are the details of Phased Manufacturing programme in each case and by when basic production would start in each case?

THE MINISTER OF PETROLEUM AND CHEMICALS AND PARLIAMENTARY AFFAIRS (SHRI SATYA PRAKASH MALAVIYA): (a) Production of monitored drugs is regularly published in the annual performance budgets of this Ministry copies of which are available in the Parliamentary Library.

(b) and (c) Names of drugs whose production was less in 1989-90 compared to 1988-89 are given in the statement. The fall in production is due to several factors including drug obsolesence, introduction of better and more potent drugs, corporate plans of the company market demand etc. The various provisions of drug policy